ImmunoPrecise Antibodies (NASDAQ:HYFT) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.01) by 600 percent. This is unchanged from the same period last year. The company reported quarterly sales of $4.124 million which beat the analyst consensus estimate of $4.000 million by 3.10 percent. This is a 53.94 percent increase over sales of $2.679 million the same period last year.